Clinical Trials on Influenza Due to Unspecified Influenza Virus in Austria

Total 199 results

GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

United States, Australia, Thailand
Ology Bioservices

Completed

Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults

Influenza | Avian Influenza

Austria, Finland
Ology Bioservices

Completed

Yearly Strain Variation Study, 2010/2011

Influenza | Seasonal Influenza

Austria
Ology Bioservices

Completed

Yearly Strain Variation Study, 2009/2010

Influenza | Seasonal Influenza

Austria
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
Pantec Biosolutions AG
Medical University of Vienna

Completed

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

Influenza in Human

Austria
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Completed

Recombinant H7 Hemagglutinin Influenza Vaccine Trial (FLU007)

Influenza, Avian

Australia
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
AVIR Green Hills Biotechnology AG

Completed

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01)

Seasonal Human Influenza

Austria
Novavax

Completed

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Avian Influenza

Australia
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Adults

Influenza | Pandemic Influenza

Austria, Germany
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
Ellume Pty Ltd

Completed

Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B

Influenza A | Influenza B

Australia
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Cocrystal Pharma, Inc.
Cocrystal Pharma Australia Pty Ltd.; Linear Clinical Research

Completed

CC-42344 Safety Study in Healthy Participants

Influenza A

Australia
SAb Biotherapeutics, Inc.

Active, not recruiting

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Influenza | Influenza Type B | Influenza Type A

United States
Ellume Pty Ltd

Completed

Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Influenza A/B

Influenza A | Influenza B

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza (PIPET A)

Pandemic Influenza

Australia
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B (PIPET B)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza (PIPET C)

Pandemic Influenza

Australia
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
Ology Bioservices

Completed

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

Influenza

Austria
AVIR Green Hills Biotechnology AG

Completed

Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

Influenza, Human

Austria
Vir Biotechnology, Inc.

Completed

Study of VIR-2482 in Healthy Volunteers

Influenza A

Australia
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Austria
Ology Bioservices

Completed

Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents

Influenza, Avian

Australia, Finland, Singapore, Spain
Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
The University of Texas Health Science Center at...
Sendero Health Plans, Inc.

Unknown

Investigating the Effectiveness of a Seasonal Influenza Vaccination Promotion Campaign for Members of a Non-Profit, Community-Based Health Insurance Plan: 2018-2019

Influenza, Vaccination

United States
Ology Bioservices

Completed

Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

Influenza | Pandemic Influenza

Austria
Ology Bioservices

Completed

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Influenza

Austria, Belgium
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005

Influenza

Austria, Germany
DiaSorin Molecular LLC

Completed

LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia

Coronavirus Disease 2019 | Influenza A | Influenza Type B

Australia
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute; Flinders University

Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults (FLU003)

Influenza

Australia
Seqirus

Completed

Phase II Study of Pandemic Influenza Vaccine

Influenza

Australia
VaxInnate Corporation

Unknown

Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Elderly Participants

Influenza

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Children

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine

Influenza

Australia
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
National Institute of Allergy and Infectious Diseases...
University of Minnesota; International Network for Strategic Initiatives in...

Completed

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

Influenza A | Influenza B

United States, Australia, Denmark, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Recruiting

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Influenza, Human

Australia
Abbott

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Influenza

Australia

3

Subscribe